Friday 24 May 2019 ,
Latest News
Parliament gets Tk 328 cr budget for FY20 | Modi claims victory, vows to build 'inclusive' India | Mobile networks in Asia, Europe suspending Huawei smartphones order | ADB provides $400mn loan for Ctg-Cox’s Bazar rail link | Maintain discipline on roads during Eid: Quader | HC summons BFSA chief over substandard foods |
27 March, 2019 10:11:42 AM / LAST MODIFIED: 27 March, 2019 10:12:19 AM

Print

Hypertension drug shows promise in liver disease

While there are therapies to treat some forms of liver diseases, including hepatitis C and autoimmune hepatitis, options have been limited for treating portal hypertension.
Independent Online Desk
Hypertension drug shows promise in liver disease
Although the study was obtained from mouse models, it was also confirmed in liver samples from humans. Photo: Getty Images

A drug used to lower blood pressure within a system of veins and inflammation could effectively treat a potentially life-threatening condition of the liver, say, researchers, including one of the Indian origin.

The study on mice showed that the drug sivelestat may lower portal hypertension - associated with cirrhosis and other chronic liver diseases - thereby improving symptoms and its outcomes.

Portal hypertension is a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver.

While there are therapies to treat some forms of liver diseases, including hepatitis C and autoimmune hepatitis, options have been limited for treating portal hypertension.


“Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease,” said Vijay Shah, the gastroenterologist at Mayo Clinic in the US.

The study, published in the journal Gastroenterology, showed deposits of a blood clot-causing protein contributed to portal hypertension.

Fibrin was formation by inflammatory cells known as neutrophils, which when slowed by sivelestat were able to decrease portal hypertension.

“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” said Moira Hilscher, a researcher at the varsity.

Although the study was obtained from mouse models, it was also confirmed in liver samples from humans.

Source: The Hindustan Times

BK

Comments

Poll
Today's Question »
State minister for power Nasrul Hamid yesterday said everyone to have access to electricity by June. Do you think the feat achievable by the timeframe?
 Yes
 No
 No Comment
Yes 50.5%
No 45.6%
No Comment 4.0%
Video
More Health Stories

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting